CEBPA and acute myeloid leukemia: In patients with AML having somatic biallelic CEBPA mutations and having underwent HSCT, five-year OS was 71.8%, which was not significantly different from that in patients with AML having somatic biallelic CEBPA mutations and receiving consolidation chemotherapy alone (82).